Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2026)

Ptc Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $19.9 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 74.44% year-over-year to $19.9 million; the TTM figure through Jun 2026 stood at $70.7 million (up 37.47% YoY), while the FY2025 annual figure was $47.0 million, down 18.09% from the prior year.
• Cost of Revenue for Q2 2026 stood at $19.9 million, down from $28.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $29.1 million in Q4 2023, with the low at $7.0 million in Q4 2025.
• The 5-year median for Cost of Revenue is $13.4 million (2022), against an average of $14.6 million.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue soared 167.31% in 2023, then tumbled 57.32% in 2025.
• Ptc Therapeutics' Cost of Revenue stood at $10.9 million in 2022, then surged by 167.31% to $29.1 million in 2023, then plunged by 44.08% to $16.3 million in 2024, then sank by 57.32% to $7.0 million in 2025, then surged by 186.63% to $19.9 million in 2026.
• Business Quant data shows PTCT's Cost of Revenue at $19.9 million in Q2 2026, $28.0 million in Q1 2026, and $7.0 million in Q4 2025.